Risk, Cure and Complications in Advanced Hodgkin Disease
|
|
- Abigayle Benson
- 5 years ago
- Views:
Transcription
1 Risk, Cure and Complications in Advanced Hodgkin Disease Sandra J. Horning Stanford University, Stanford, CA Current therapy for Hodgkin disease is aimed at high cure rates and optimal survivorship. Although intensified chemotherapy with the escalated BEACOPP regimen resulted in higher rates of cure and survival compared with COPP/ABVD in the high-profile HD9 randomized controlled trial (RCT), this regimen has not been universally adopted by patients and physicians due to the attendant increased risks of early and late complications. Appropriately, questions emerge as to whether the results of this trial should be interpreted as establishing the superiority of BEACOPP over the current standard ABVD therapy, and whether clinical or biologic prognostic factors can better select patients for more intensive treatment. The widespread availability and high predictive accuracy of functional imaging with PET scans has led to promising, preliminary studies assessing early response to therapy with this diagnostic tool. In this review, the characteristics and outcomes of patients treated with ABVD in RCT will be made and compared with COPP/ABVD in HD9; clinical and biologic prognostic factors will be discussed, including PET imaging; and newer strategies targeted at minimizing treatment complications while maximizing cure rates will be discussed. Although enthusiasm for PET imaging is great, the challenges for using this diagnostic tool for risk-adapted therapies are substantial. Importantly, physicians and patients should be aware of these challenges, support the RCT that seek to address them, and carefully weigh risks and benefits for individual patients. Introduction The treatment of Hodgkin disease (HD) at any stage of presentation is highly successful, and survival statistics demonstrate significant gains from compared with Over the last three decades, management has evolved from a heavy reliance on extended field irradiation supplemented with alkylating agent-based chemotherapy to anthracycline-based chemotherapy with selective consolidation with involved field irradiation, often at a lower dose. In the past decade, superior outcomes in earlystage disease have been reported in individual clinical trials with combined modality therapy versus chemotherapy alone in early-stage disease and with more intensive chemotherapy in advanced-stage disease, but at the cost of an increased risk for early and late morbidities. 2-5 These experiences have resulted in a tension between the desire to cure as many patients as possible with primary therapy and the desire to render survivors with as few early and late adverse effects as possible. Additional advances within the past decade have included the study and use of positron emission tomography (PET) scans as more accurate predictors of disease status in HD and characterization of HD on the cellular and molecular levels. 6-8 There is, naturally, a great desire to bring this new knowledge to bear in the clinical management and to specifically address the noted tension. From this background, three questions emerge: (1) Is it appropriate to extrapolate the results of COPP/ ABVD in the German Hodgkin Lymphoma Study Group (GHSG) HD9 trial to conclude that BEACOPP (cyclophosphamide, adriamycin, etoposide, vincristine, bleomycin, procarbazine, prednisone) is superior to ABVD (adriamycin, bleomycin, vincristine, dacarbazine)? (2) Can we risk-adapt, that is, distinguish clinical or biologic prognostic features to identify patients who will benefit or will be harmed from more intensive treatment? (3) Can newer therapeutic strategies result in both higher survival rates and better survivorship? ABVD in Randomized Controlled Trials The ABVD combination, introduced in the 1970s by Bonadonna and colleagues, became the standard of care in HD based on randomized clinical trials conducted by the U.S. cooperative groups The more recent Intergroup study reported by Duggan et al had no upper age limit, and older age had a major impact on efficacy and toxicity. In this study, 36% of patients were older than 40 years (Table 1). 11 Only stage III-IV patients were eligible but patients relapsing after prior radiation therapy were included. Based on the standards of the time, treatment was delivered with dose modifications for peripheral blood counts, and growth factors were not to be used to maintain optimal dose and schedule. The failure-free survival (FFS) at 5 years was 63% and overall survival (OS) was 81% in the ABVD arm (n = 412) (Table 2). FFS was inferior for patients who were older, had stage IV disease (45% of the population) and had received prior radiation. No radiotherapy was planned in this study. Of note, 75% of the deaths occurred among those older than 55 years. Retrospective application of the Inter- Hematology
2 Table 1. Patient characteristics: ABVD or COPP/ABVD in randomized controlled trials. U.S. UK Italian GHSG Intergroup LY09 Intergroup HD9 ABVD ABVD ABVD COPP/ABVD N = 412 N = 406 N = 122 N = 260 Age Upper bound 77 y 68 y 65 y Median 35 y 31 y 32 y Reported 36% > 40 y 23% > 45 y 16% > 50 y Male sex, % Stage, % IV II Prior therapy Yes No No No IPS, % 0, * 2, * * *Adjusted to 100% for available patients. Abbreviations: ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; COPP, cyclophosphamide, vincristine, prednisone, procarbazine; IPS, International Prognostic Score Table 2. Treatment delivery and results: ABVD or COPP/ ABVD in randomized controlled trials. U.S. UK Italian GHSG Intergroup LY09 Intergroup HD9 ABVD ABVD ABVD COPP/ABVD N = 412 N = 406 N = 122 N = 260 FFS, % 63 (5 y) 75 (3 y) 85* (5 y) 69 (5 y) FFS, % IPS 0,1 76, 72 ~86 NA 79 IPS 2,3 81, 69 ~75 NA 67 IPS , 67 ~74 NA 59 OS, % 81 (5 y) 90 (3 y) 90 (5 y) 83 (5 y) Reported NR > Median treatment relative relative treatment delivery dose dose duration 46.3 intensity intensity wk vs 30 wk planned Irradiated, % *See text for explanation; FFS=78%. Extrapolated from published survival curves. Abbreviations: ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; COPP, cyclophosphamide, vincristine, prednisone, procarbazine; FFS, failure-free survival; IPS, International Prognostic Score; OS, overall survival; NR, not reported national Prognostic Score (IPS), which was less favorably distributed than expected (Table 1), did not correlate with FFS. Although efficacy was similar to the MOPP (mechloroethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine)/abv combination, this randomized controlled trial (RCT) was closed prematurely due to an increased risk of death and second malignancy with MOPP/ABV. 11 Gobbi and colleagues tested ABVD in a three-arm Italian study involving 122 ABVD patients with stage IIB-IV disease. 11,12 In this study, the age cap was 65 years (although the upper age boundary of treated patients was 68 years) and the median age was 31 years, with 23% patients older than 45 years. Radiation therapy was delivered to patients with bulky disease or to a maximum of two sites of persistent radiographic disease for partial response (PR) or uncertain complete response (CRu) patients. Six cycles of chemotherapy were given and were supported by growth factor for severe neutropenia. The IPS distribution was as expected despite the fact that 34% of patients had stage IIB disease. Stage IV disease was reported in 24%. At 5 years, the freedom from progression was 85% and the OS was 90%. Only 3% of patients experienced disease progression. In this study, an unusual definition of FFS was used, in which PR was scored as treatment failure. However, using that definition, the FFS was 78% at 5 years. The ABVD regimen was tested by Johnson and colleagues as the standard arm in randomized comparisons with multidrug combinations (ChlVPP/PABlOE, ChlVPP/ EVA). 13 Adults of all ages were eligible, such that the upper age boundary was 77 years and the median age was 35 years. Patients with advanced disease and those with earlystage disease requiring systemic chemotherapy (based on risk factors) were eligible. Overall, 19% patients had stage IV disease. Patients received 6 to 8 cycles of chemotherapy, supported by growth factors to maintain optimal dosing, and radiation was delivered to sites of bulky or residual disease. Of note, relative dose intensity was more than 80%, and 44% used growth factors. At 3 years, the estimated event-free survival was 75% for the 406 ABVD-treated patients, and the OS was 90%. Outcomes were inferior for patients older than 45 years with the multidrug combinations (in agreement with the U.S. Intergroup results) compared to ABVD, whereas no significant differences were seen in the overall study according to IPS. In this study, ABVD emerged as the preferred regimen based on superior tolerance. With current anti-emetics and vascular access, ABVD is considered a well-tolerated regimen. In the U.S. Intergroup trial, pulmonary toxicity as defined by protocol occurred in 30% of ABVD patients, with an increased incidence in those who were older and had received prior radiation. A small number of fatal events related to bleomycin pulmonary toxicity has been reported in multiple studies; the incidence of this in the Intergroup study was 2%. Fatal respiratory toxicity in the UK study was reported as 1.5%. Remarkably, no cases of acute leukemia were recorded among any of the patients treated with ABVD alone in the Intergroup study, the UK study or the Italian study, consistent with prior reports that ABVD does not increase the risk of subsequent leukemia. Early data suggested that fertility among both men and women is maintained with ABVD, 198 American Society of Hematology
3 although this has generally been an extrapolation from semen analyses and reports of menstrual function, alone or combined with hormone measurements. Recently, Hodgson et al reported that 70% of women (n = 36) treated with ABVD were able to conceive within 12 months after 4 to 6 treatment cycles compared with 75% of controls. 14 BEACOPP in Randomized Controlled Trials Diehl and colleagues introduced standard and escalated BEACOPP based upon a mathematic model indicating the potential for an increased cure rate with dose intensification. 2 BEACOPP combines etoposide with traditional cytotoxic agents, cyclophosphamide and procarbazine, as well as doxorubicin. Growth factors are integral to the delivery of escalated BEACOPP, which features major intensification of cyclophosphamide and etoposide. The HD9 study, in which standard and escalated BEACOPP were compared with COPP/ABVD, has been presented, published, and updated on several occasions. 2,15 Eligible patients were 15 to 65 years old with stage IIB-IIIA disease with risk factors or with IIIB-IV disease. Patients received 8 cycles of chemotherapy followed by 36 Gy radiotherapy to sites of bulky or residual disease. Table 3 tabulates data from the HD9 study comparing outcomes of standard and escalated BEACOPP with COPP/ABVD. Given the caveats of comparison due to early closure of the COPP/ABVD arm, escalated BEACOPP yields statistically superior FFS and OS compared with COPP/ABVD at 5 years, and a recent update indicates that its superiority has only increased by 10 years. 15 The survival benefit is remarkable, especially considering that ABVD did not demonstrate superior survival compared to MOPP, albeit in a smaller trial. 16 The IPS correlated with treatment efficacy in each treatment arm in Table 3. DH9 study results according to treatment arm and International Prognostic Score (IPS). Standard Escalated BEACOPP BEACOPP COPP/ABVD N = 469 N = 466 N = y 10 y 5 y 10 y 5 y 10 y FFS, % IPS 0, * 79 78* IPS 2, IPS OS, % IPS 0, IPS 2, IPS *P =.015 P =.0001 P =.020 P =.0027 Abbreviations: BEACOPP, cyclophosphamide, adriamycin, etoposide, vincristine, bleomycin, procarbazine, prednisone; COPP/ABVD, cyclophosphamide, vincristine, prednisone, procarbazine/adriamycin, bleomycin, vinblastine, dacarbazine; FFS, failure-free survival; OS, overall survival. this study. Based on these outstanding efficacy data, escalated BEACOPP became the new standard treatment in Germany for patients 65 years old or less. The HD9 elderly study was simultaneously conducted in 75 patients 65 to 75 years old and compared COPP/ ABVD with standard BEACOPP. 17 Escalated BEACOPP was considered to be unsuitable for patients older than 65 years. In contrast to the results in younger patients, there was no difference in the treatment arms and the results were unsatisfactory in both arms, with 46% FFS and 50% OS. Toxicity was unacceptable with standard BEACOPP, which was associated with 21% acute fatal toxicity. As anticipated, the toxicity of escalated BEACOPP was considerable, including nearly universal grade 3-4 neutropenia, 70% thrombocytopenia, 66% grade 3-4 anemia, and 22% grade 3-4 infections. These complications were more apparent in the final four treatment cycles. At 10 years, secondary leukemia was reported in 14 patients treated with escalated BEACOPP (3.2%). 4 Fertility was compromised in men and women as anticipated. 18 A desire to ameliorate these adverse effects while maintaining the therapeutic benefit led to subsequent GHSG studies as outlined below. Extrapolating the COPP/ABVD Results to ABVD Table 1 makes apparent the variation in the patient populations studied with ABVD and the COPP/ABVD arm of the HD9 study. The Intergroup trial stands out as having more stage IV patients, a higher proportion of IPS 4-7 patients, older-age patients, and the inclusion of patients who had failed prior radiotherapy. The United Kingdom study also has older patients but fewer stage IV patients. Despite these differences, the British, Italian and German studies are relatively consistent with regard to IPS scores. In Table 2, the efficacy and treatment delivery of ABVD and COPP/ ABVD in these studies is described. The FFS data are inconsistent across the ABVD studies, and the reported dose intensity of drug delivery varied. Analyses of risk factors was inconsistent with regard to IPS score; advanced age and stage IV disease were recognized as prognostic factors in the U.S. Intergroup study. The explanation for the lower FFS in the Intergroup study is subject to speculation, but might relate to the intensity of delivered therapy as well as a less favorable patient population. Neutropenia is common with the ABVD regimen and, historically, dose reductions were based on total white blood count on days 1 and 15. Several authors have demonstrated that dose intensity can be maintained with the addition of growth factors Recently, Evens et al have suggested that full doses of ABVD can be given safely despite neutropenia and without growth factors. In a single institution experience, they were able to deliver ABVD on a median 28.2-day schedule and maintain 99% dose intensity. 15 Further, their results in advanced-stage patients (n = 40) were excellent: 87% FFS at 5 years. These results are of interest based on theoretical concerns that G- CSF exacerbates severe lung injury in preclinical models Hematology
4 and retrospective data relating older age and G-CSF use with bleomycin-associated lung toxicity. Notably, COPP/ABVD cycles in the HD9 study were delivered over a median 46.3 days compared with the planned 30 days. As described by Diehl et al, this compares with a median cycle length of 24.3 days for standard BEACOPP and 24.7 days for escalated BEACOPP. 2 Taken together, these RCT results suggest that it is not appropriate to extrapolate the COPP/ABVD results from the HD9 study to suggest that they are a fair assessment of modern ABVD treatment. The marked variation in the patient populations (particularly with regard to age and stage) and the differences in treatment delivery lead to the conclusion that a RCT comparing ABVD with BEACOPP, as is in progress in the European Organization for Research on Treatment of Cancer (EORTC), is necessary. Clinical and Biologic Prognostic Factors The IPS reported by Hasenclever et al. resulted from a large, multinational effort coordinated by the GHSG. 22 The IPS was variably prognostic in the studies described above, but it nicely separated outcomes in the HD9 study and was also found to be prognostic by other investigators. In Table 3, the HD9 results are reported by IPS by efficacy measures at 5 and 10 years. Remarkably, the favorable impact of escalated BEACOPP only increases over time, whereas the benefit of standard BEACOPP appears to wane. 15 The most strikingly apparent finding is that it is necessary to treat patients with all IPS scores to achieve the benefit from escalated BEACOPP. The benefits are not restricted to high-risk disease. Accordingly, selection of high-risk patients is not an effective strategy to discern the subset of patients who benefit from dose intensification. The other conclusion that can be drawn from Table 3 is the relatively unfavorable outcome for IPS 4-7 patients. At 10 years, 30% of patients treated with escalated BEACOPP are estimated to be deceased. More effective strategies are needed for this subgroup. In addition, as described above, older age is a consistently adverse prognostic factor. Differences in both treatment delivery and underlying biology may contribute to poor outcomes. 23 Clearly, BEACOPP is not indicated in patients older than 65 years, where it appears to be harmful. 17 In contrast, treatment with ABVD in optimal doses appears to yield better results than alternative strategies. 11,24 Tissue-based and serologic biomarkers have been extensively explored as measures of prognosis in Hodgkin lymphoma (HL). Variations in morphology, classical phenotypic markers (CD15, CD20), proteins associated with apoptosis (bcl-2), T-cell composition in the microenvironment, and other tissue markers have been reported to be associated with prognosis. However, none of these has gained traction due to inconsistent results, small populations, variable therapies, and the greater strength and reliability of clinical prognostic factors. Other investigators proffered measures of tumor burden, such as β2 microglobulin and soluble CD30. The significance of Epstein- Barr virus expression by in situ hybridization has emerged as interesting marker that may be neutral or favorable in younger patients but is unfavorable in older patients, where it may serve as an indicator of immunodeficiency. 25 Assessment of cytokine expression in the serum (IL-10) and cytokine polymorphisms has also correlated with clinical outcomes. 26,27 Although these are important and promising avenues of investigation, at this time biomarkers do not appreciably impact therapeutic decision making in HD. Early as well as end of therapy response has long been recognized to predict outcome in HD. However, the common occurrence of residual radiographic abnormalities hampered response assessment. PET using [ 18 F] fluorodeoxyglucose (FDG) has emerged as a powerful functional imaging tool for restaging and response assessment. 28 Studies in advanced HD, in particular, indicate that PET is highly predictive at the conclusion of chemotherapy. PET is also highly predictive of outcome in advanced HL after 2 cycles of chemotherapy and is more powerful than conventional clinical prognostic parameters. 7,29 Recently, a series of 260 consecutive patients enrolled in prospective studies of PET imaging in Denmark and Italy were reported together. 30 Patients with stage IIA with risk factors and stages IIB-IV without age restriction were enrolled. All but 11 patients received ABVD. PET scans were obtained at baseline and after 2 cycles of therapy with no change in therapy planned based on the results. The population was quite favorable, with only 17% stage IV patients, and the IPS distribution was 41% 0-1, 50% 2-3, and 9% 4-7. At 2 years, progression-free survival was more than 90% for IPS 0, more than 80% for IPS 1 and 2, and fell to approximately 60% for IPS 3 and above. PET scans in the Gallamini et al study were visually interpreted by consensus with clinical input and considered to be negative if minimal residual uptake was present (defined as equal to or only slightly higher than the mediastinal blood pool or standardized uptake value [SUV] of ). PET-2 scans were positive in 50 (19%) patients, 13% of IPS 0-2 patients, and 38% of IPS 3-7 patients. PET- 2 scans were strikingly predictive of status at 2 years, with FFS of 95% for negative versus 12.8% for positive patients (P <.001). Outcomes were equally predictive among low and high IPS patients and PET-2, stage IV and age older than 45 years were most predictive of outcome in multivariate analyses. PET-2 was by far the strongest predictive factor. Taken together, these data indicate that age is a consistent clinical prognostic factor and that elderly patients may be harmed by more intensive strategies. The IPS defines patients generally at higher risk for treatment failure, but patients who benefit from more intensive treatment are found in all IPS strata. Patients with IPS 4-7 continue to pose a challenge, as 30% fail escalated BEACOPP by 10 years. Finally, early PET imaging, as reported in selected centers, is the most prognostic determinant of treatment success or 200 American Society of Hematology
5 failiure. These early PET data are consistent with older data indicating that the rate of response by conventional measures is prognostic, preclinical models in curative disease, and clinical experience with tumor markers in another highly curable malignancy, testicular cancer. New Therapeutic Strategies to Attain High Cure Rates and Optimal Survivorship Modifications of the BEACOPP regimen were tested in subsequent GSHG studies. The HD15 study compared 8 cycles of escalated BEACOPP with 4 cycles of escalated and 4 cycles of standard BEACOPP. In presented but unpublished analyses, these treatment arms appeared to be equally effective and confirmed the original escalated BEACOPP results. Further, outcomes after a second randomization to radiotherapy or observation were not different. 15 Another modification of BEACOPP is a 14-day schedule supported by growth factors. 31 As cumulative doses are less with these modifications, it is anticipated that the risk of secondary leukemia would be less, and that is what has been observed to date. Likewise, the degree of acute hematologic toxicity is lessened. Effects on male and female fertility remain concerns, however. Efficacy with these modifications has been excellent, maintaining FFS above 85%. However, it will be important to carefully assess these newer strategies as the mature data become available for full analysis. The appeal of the PET-2 data described above is the opportunity to adjust treatment early in the therapeutic course based on the hypothesis that dose intensification will effect a higher cure rate. Certainly, the incremental efficacy of dose intensification was established in the HD9 study and also serves as the basis for treating recurring HD with myeloablative chemotherapy and stem cell transplantation. Dose adjustment could be approached by starting with dose intense therapy (i.e., escalated BEACOPP) and then de-escalating based on PET-2 or, alternately, escalating to dose-intense treatment based on PET-2. Dann et al studied the former approach in 108 patients with HD dichotomized as intermediate risk (n = 69, IPS 0-2) or high risk (n = 39, IPS 3-7). 32 Intermediate-risk patients received standard BEACOPP and high-risk patients received escalated BEACOPP with a plan to crossover based on the results of a PET or Gallium scan after 2 cycles. Of 11 intermediate-risk patients with positive studies after standard BEACOPP, 10 crossed over, of whom 2 progressed. Six of the 58 scan-negative patients remaining on standard BEACOPP had progressive disease, yielding an 84% progression-free survival for the cohort of 69 patients. Among the 39 high-risk patients, just 7 continued with escalated BEACOPP and, for the entire high-risk cohort, there were 4 treatment failures and one early discontinuation. Although the sample size is small, this interesting study suggests that risk-adapted treatment is feasible and effective. Nonetheless, there are several caveats to risk-adapted approaches that must be considered (Table 4). First the ability to reproducibly interpret PET scans with the 92% accuracy reported by Gallamini et al must be confirmed. 29 In contrast to prior reports from these authors, the interpretations were made by consensus, incorporated clinical information, and in an unreported number, over-ruled prior interpretations. It was not stated that the reviewers were fully blinded. In particular, the concept of minimal residual uptake, interpreted by blood pool and with an SUV of 2-3.5, has not been adopted in other risk-adapted studies, such as those in non-hodgkin lymphoma. Another issue is one of strategy. De-escalation, as in the Dann et al study, does not protect patients from the higher risks of intensive treatment, whereas escalation may not fully recapture the benefit of more intensive treatment. 32 The ability to successfully treat PET-positive patients with a second-line or cross-over treatment has not been established. Whether or not it is essential to treat patients with HD with aggressive therapy from the time of diagnosis, as promoted by the GHSG, is an unanswered question. Further, it is likely that patients with PET-2 positive studies after ABVD are also patients at greatest risk for failing escalated BEACOPP (most Table 4. Challenges for therapy risk-adapted by early positron emission tomography (PET). PET scan acquisition and interpretation Escalation of therapy De-escalation of therapy Study design and conduct Consensus versus standard reading Use of other clinical information Adjudication of conflicts Minimal residual uptake Visual versus SUV versus rate of change Technical: equipment, recording Inexperienced readers Factoring likelihood of false positives and negatives Not known to be effective Early PET-positive may also predict failure of intensive therapy Not an option for elderly Does not eliminate all risks (acute toxicity, sterility) Not known to be effective Assumptions made on clinical risk Assumptions made on efficacy of cross-over design Necessity for blinding Equipoise for patients and physicians based on published and presented results Hematology
6 notably IPS 4-7), as has been established prior to doseintense therapy and autotransplantation. Of course, riskadapted approaches do not address the most challenging population, the elderly. Finally, risk-adaption based on early PET may not reveal cases that relapse later after treatment, as seen in the approximately 10% of PET-2 negative patients who progressed in the Dann et al study. 32 These caveats should not deter investigators from meeting the challenges to rigorously study risk-adaption in clinical trials so that results can disseminate to practicing physicians and their patients. However, during the conduct of such studies, it will be essential to have a control arm for which the results of early functional imaging will not trigger a clinical decision. It will also be important that the physician community fully understands the issues and can communicate them to their patients in order for these important RCT to be conducted expeditiously. Correspondence Sandra Horning, MD, Stanford University, 875 Blake Wilbur Drive, Suite CC-2338, Stanford, CA ; phone (650) ; fax (650) ; sandra.horning@stanford.edu References 1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, CA Cancer J Clin. 2007;57: Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin s disease. N Engl J Med. 2003;348: Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23: Josting A, Wiedenmann S, Franklin J, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin s disease: a report from the German Hodgkin s Lymphoma Study Group. J Clin Oncol. 2003;21: Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin s Lymphoma Study Group. J Clin Oncol. 2005;23: Re D, Thomas RK, Behringer K, et al. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood. 2005;105: Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107: Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin s disease patients. Ann Oncol. 2006;17: Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36: Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327: Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin s disease: report of an intergroup trial. J Clin Oncol. 2003;21: Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005;23: Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin s lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN ). J Clin Oncol. 2005;23: Hodgson DC, Pintilie M, Gitterman L, et al. Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol. 2007;25: Diehl V, Franklin J, Tesch H, et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin s disease in the HD9 trial of the German Hodgkin s Lymphoma Study Group (GHSG). Proc ASCO. 2007; abstract no Canellos GP, Niedzwiecki D: Long-term follow-up of Hodgkin s disease trial. N Engl J Med. 2002;346: Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005;16: Sieniawski M, Josting A, Breuer K, et al. Fertility in male patients with Hodgkin s disease - results from the German Hodgkin Lymphoma Study Group (GHSG) [abstract]. Blood. 2004;104:1315a. 19. Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol. 2007;137: Chand VK, Link BK, Ritchie JM, et al. Neutropenia and febrile neutropenia in patients with Hodgkin s lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. Leuk Lymphoma. 2006;47: Boleti E, Mead GM. ABVD for Hodgkin s lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol. 2007;18: Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin s disease. International Prognostic Factors Project on Advanced Hodgkin s Disease. N Engl J Med. 1998;339: Engert A, Ballova V, Haverkamp H, et al. Hodgkin s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin s Study Group. J Clin Oncol. 2005;23: Landgren O, Algernon C, Axdorph U, et al. Hodgkin s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica. 2003;88: Keegan TH, Glaser SL, Clarke CA, et al. Epstein-Barr virus as a marker of survival after Hodgkin s lymphoma: a population-based study. J Clin Oncol. 2005;23: Hohaus S, Giachelia M, Di Febo A, et al. Polymorphism in cytokine genes as prognostic markers in Hodgkin s lymphoma. Ann Oncol. 2007;18: Casasnovas RO, Mounier N, Brice P, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin s lymphoma: a study from the Groupe d Etude des Lymphomes de l Adulte. J Clin Oncol. 2007;25: American Society of Hematology
7 28. Juweid ME. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006:; Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin s disease. Haematologica. 2006;91: Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2- [18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage hodgkin s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25: Engert A, Bredenfeld H, Dohner H, et al. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin s lymphoma: results of a phase II study. Haematologica. 2006;91: Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood. 2007;109: Hematology
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationGerman Hodgkin Study Group
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of
More informationABVD or BEACOPP for advanced Hodgkin lymphoma. Not to BEACOPP. Massimo Federico University of Modena and Reggio Emilia Italy
ABVD or BEACOPP for advanced Hodgkin lymphoma Not to BEACOPP Massimo Federico University of Modena and Reggio Emilia Italy What is the best Induction Therapy for Advanced Hodgkin Lymphoma? How to treat
More informationPET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
More informationPrinted by Martina Huckova on 10/3/2011 3:04:43 PM. For personal use only. Not approved for distribution. Copyright 2011 National Comprehensive
NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform NCCN consensus. Category 2A: The recommendation
More informationEnd-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin s lymphoma
original article Annals of Oncology 22: 910 915, 2011 doi:10.1093/annonc/mdq549 Published online 15 October 2010 original article End-of-treatment but not interim PET scan predicts outcome in nonbulky
More informationInterim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal
Interim PET Hodgkin s Disease Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal Why is this a Question? Early Advanced ipet ABVD + RT ABVD Pos Neg ABVD Beacopp Escalation Salvage Deescalation Talk outline
More informationHodgkin Lymphoma Status of the art of treatment
11.05.2016 1 Hodgkin Lymphoma Status of the art of treatment Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Question No 1: Which statement regarding 1 st line treatment of early
More informationAdvanced stage HL The old and new match: BEACOPP
27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment
More informationThe Present: Optimizing Therapy Too Much or Too Little?
CLINICAL ADVANCES IN HODGKIN LYMPHOMA The Present: Optimizing Therapy Too Much or Too Little? Nancy L. Bartlett 1 1 Siteman Cancer Center, Washington University, St. Louis, MO Despite the use of less toxic
More informationRadiation therapy has a dramatic effect on lymphomas, and has played an important role in treating Hodgkin
COUNTERPOINTS Current Controversies in Hematology and Oncology Can Radiotherapy Be Omitted in Patients With Localized Hodgkin Lymphoma? Radiation therapy has a dramatic effect on lymphomas, and has played
More informationPractical Application of PET adapted Therapy in Hodgkin Lymphoma
Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,
More informationEvolving Approaches to Primary Treatment of Hodgkin Lymphoma
Evolving Approaches to Primary Treatment of Hodgkin Lymphoma Joseph M. Connors Two challenges confront the clinician treating Hodgkin lymphoma today: achieving a high level of effectiveness while minimizing
More informationHodgkin Lymphoma-Stage III and IV EVIDENCE TABLE
. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008. 2. Lister TA, Crowther D, Sutcliffe SB, et al. Report
More informationLimited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment
HODGKIN LYMPHOMA: CLINICAL CHALLENGES Limited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment John Radford 1 1 Professor of Medical Oncology, Christie Hospital and The University of
More informationXVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma
Hematological Oncology Hematol Oncol 2015; 33: 90 95 Published online in Wiley Online Library (wileyonlinelibrary.com).2226 Supplement Article XVIII. Management of nodular lymphocyte predominant Hodgkin
More informationA Practical Guide to PET adapted Therapy for Hodgkin Lymphoma
Hello. My name is Peter Johnson. I am a Professor of Medical Oncology in Southampton in the UK and I am speaking today on behalf of Managing Hodgkin Lymphoma, and particularly, I am going to talk about
More informationabstract n engl j med 374;25 nejm.org June 23,
The new england journal of medicine established in 82 June 23, 26 vol. 374 no. 25 Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin s Lymphoma Peter Johnson, M.D., Massimo Federico, M.D.,
More informationABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS
ABVD versus BEACOPP arguments for ABVD Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS DISCLOSURES HONORARIAS: Takeda, roche GRANT RESEARCH : Millenium Takeda, AMGEN ABVD the standard chemotherapy
More informationSerum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin s lymphoma
Original article Annals of Oncology 13: 1908 1914, 2002 DOI: 10.1093/annonc/mdf333 Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin s lymphoma
More informationHodgkin Lymphoma Which Group of Patients benefits from the use of BEACOPP. Volker Diehl for the German Hodgkin Study Group
Hodgkin Lymphoma Which Group of Patients benefits from the use of BEACOPP Volker Diehl for the German Hodgkin Study Group Moscow 25.October 2007 HD8 trial design CS IA, IB, IIA,B with risk factors Random
More informationResponse-adapted frontline therapy for Hodgkin lymphoma: are we there yet?
HODGKIN LYMPHOMA: TREATMENT TODAY AND THE CHALLENGE FOR TOMORROW Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet? Peter W. M. Johnson Cancer Research UK Centre, University of
More informationNIH Public Access Author Manuscript Expert Opin Pharmacother. Author manuscript; available in PMC 2011 December 1.
NIH Public Access Author Manuscript Published in final edited form as: Expert Opin Pharmacother. 2010 December ; 11(17): 2891 2906. doi:10.1517/14656566.2010.515979. Hodgkin s Lymphoma Therapy: Past, Present,
More informationTreatment of Forty Adult Patients with Hodgkin Disease; Baghdad Teaching Hospital Experience
Original Article Treatment of Forty Adult Patients with Hodgkin Disease; Baghdad Teaching * Alaadin S. Naji* Ahmed A. AL - Saffar* Mazin A. Shubbar* Bassam F. Matti* Adil Siwan* Ammar F. Majeed* Ali M.Jawad*
More informationTreatment of Early Stage Hodgkin Lymphoma. Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research
Treatment of Early Stage Hodgkin Lymphoma Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research Conflict of Interest Disclosure I hereby declare the following
More informationComparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL):
Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial H. Eghbali, P.
More informationFirst Line Management of Classical Hodgkin Lymphoma
First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /
More informationRECENT APPROACHES IN THE TREATMENT OF HODGKIN S LYMPHOMA. Luděk Raida
Volume 142, 1999 13 RECENT APPROACHES IN THE TREATMENT OF HODGKIN S LYMPHOMA Luděk Raida Haemato-oncology Department of University Hospital, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic Received August
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationOne, the UK RAPID trial, including patients with early stage disease stage 1 and 2A nonbulky.
Martin Hutchings, MD, PhD Department of Hematology The Finsen Centre, National Hospital Copenhagen University Hospital Copenhagen, Denmark Welcome to Managing Hodgkin Lymphoma. My name is Martin Hutchings.
More informationTHE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982)
EORTC Lymphoma Group THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982) J. Thomas, C. Fermé, E.M. Noordijk, H. Eghbali and M. Henry-Amar 7th International
More informationFirst line Treatment of HL: Differential Treatment Strategies in Newly Diagnosed Patients with Early versus Advanced Stage Disease Presented
[Editor s note: Dr. Even's video transcript has been edited to improve readability] you today about the management of Hodgkin lymphoma in 2016. Welcome to Managing Hodgkin Lymphoma. My name is Andy Evens,
More information2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA
2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA SUSQUEHANNA HEALTH David B. Nagel, M.D. April 11, 2008 Hodgkin s lymphoma was first described by Thomas Hodgkin in 1832. It remained an incurable malignancy until
More informationHodgkin Lymphoma-Unfavorable Clinical Stage I and II EVIDENCE TABLE
. Kaplan HS. Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease. Cancer Res. 966;6(6):-4.. Rosenberg SA, Kaplan HS. Evidence for an orderly progression in the spread of Hodgkin's
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer
More informationPrimary treatment of Hodgkin s disease
DOI: 10.1093/annonc/mdf653 Primary treatment of Hodgkin s disease G. P. Canellos Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA Introduction Therapeutic research in human
More informationRT in Hodgkin Lymphoma
RT in Hodgkin Lymphoma Lesser is better? Philip Poortmans, M.D. Ph.D. Radiation oncologist Tilburg, The Netherlands Radiation dose in Hodgkin Lymphoma Introduction Current evidence Guidelines 1.0 Early
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 24 AUGUST 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Early Interim 2-[ 18 F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International
More informationREVIEW ARTICLES ABSTRACT. EJD and RBS contributed equally to this manuscript.
REVIEW ARTICLES A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin
More informationLymphocyte-Depleted Classical Hodgkin s Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group
Published Ahead of Print on September 12, 211 as 1.12/JCO.211.36.473 The latest version is at http://jco.ascopubs.org/cgi/doi/1.12/jco.211.36.473 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R
More informationHodgkin s Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease
Hodgkin s Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease Volker Diehl, Harald Stein, Michael Hummel, Raphael Zollinger, and Joseph M. Connors Hodgkin s lymphomas
More informationHodgkin. The PET World. Sally Barrington
Hodgkin The PET World Sally Barrington PET-CT Staging in HL PET-CT changes stage 15-30% RATHL - Advanced HL 1171 pts Stage by PET-CT compared with cect and BMB 20% stage change; upstaging 14% Most upstaging
More informationOn behalf of the Israel Cooperative Lymphoma Group. A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler, I. Ben-Bassat and A.
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan for patients with advanced highrisk Hodgkin s lymphoma A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY
ROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY EPIDEMIOLOGY HODGKIN LYMPHOMA - INCIDENCE EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY BY AGE NUMBER OF PEOPLE
More informationGruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera S. Croce e Carle, Cuneo
Sponsor Principal Investigator Protocol Coordinators Coordinating Centre Writing committee CRO Gruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera
More informationHodgkin Lymphoma Review of characteristics and treatment of elderly patients
Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Boris Böll M.D. German Hodgkin Study Group (GHSG) University Hospital Cologne OS of HL patients in all stages 1960-1967 Courtesy
More informationOriginal Articles. Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin s disease
RUPALI et al. : AETIOLOGY OF PROLONGED FEVER IN HIV-INFECTED ADULTS Original Articles 189 Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for
More informationNCCP Chemotherapy Protocol. INDICATION ICD10 Protocol Code Hodgkin s Lymphoma C a
ABVD THERAPY INDICATIONS FOR USE: INDICATION ICD10 Protocol Code Hodgkin s Lymphoma C81 00290a ELIGIBILTY: Indications as above ECOG 0-3. Patients with an ECOG 4 may be considered for treatment at the
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 21 JULY 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage
More informationHodgkin s lymphoma: news from an old disease
review Hodgkin s lymphoma: news from an old disease J.M.M. Raemaekers 1*, R.W.M. van der Maazen 2 Departments of 1 Haematology and 2 Radiotherapy, Radboud University Nijmegen Medical Centre, Nijmegen,
More informationEarly interim PET (PET2) in Hodgkin Lymphoma patients treated with ABVD. An International Validation Study (IVS).
Early interim PET (PET2) in Hodgkin Lymphoma patients treated with ABVD. An International Validation Study (IVS). A Gallamini Hematology Department and BMT Unit, Santa Croce Hospital Cuneo - Italy S. Barrington
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
PET Scanning in Oncology to Detect Page 1 of 9 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Positron Emission Tomography (PET) Scanning: In Oncology to Detect
More informationjournal of medicine The new england ABVD versus BEACOPP for Hodgkin s Lymphoma When High-Dose Salvage Is Planned A BS TR AC T
The new england journal of medicine established in 1812 july 21, 2011 vol. 365 no. 3 versus for Hodgkin s Lymphoma When High-Dose Salvage Is Planned Simonetta Viviani, M.D., Pier Luigi Zinzani, M.D., Alessandro
More informationClinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma
Original Article Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma Authors: Shinichi Makita 1, 4, Dai Maruyama 1, Akiko Miyagi Maeshima 2, Hirokazu Taniguchi 2, Ken-ichi Miyamoto
More informationPrinciples of Chemotherapy in Hodgkin Lymphoma
Principles of Chemotherapy in Hodgkin Lymphoma 9 Patrice Carde and Peter Johnson Contents 9.1 Historical Introduction... 141 9.2 Chemotherapy Applied to Advanced Stage HL: Theories and Practice... 142
More informationNavigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
Welcome to Managing Hodgkin Lymphoma. I am Dr. John Sweetenham from Huntsman Cancer Institute at the University of Utah. In today s presentation, I will be discussing navigating treatment pathways in relapsed
More informationHODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)
HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff
More informationElderly Patients with Hodgkin s Lymphoma: FIL experience. Massimo Federico University of Modena and Reggio Emilia
Elderly Patients with Hodgkin s Lymphoma: FIL experience Massimo Federico University of Modena and Reggio Emilia RESULTS OF VbMp CHEMOTHERAPY REGIMEN IN ELDERLY PATIENTS WITH HODGKIN DISEASE: THE GISL
More informationTherapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group
From bloodjournal.hematologylibrary.org by RAUL RIBEIRO on March 31, 2014. For personal use only. 2014123: 1658-1664 doi:10.1182/blood-2013-07-512657 originally published online January 29, 2014 Therapy-related
More informationPET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationLow acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkins disease
Ann Hematol (2004) 83:176 182 DOI 10.1007/s00277-003-0727-9 ORIGINAL ARTICLE O. Brosteanu D. Hasenclever M. Loeffler V. Diehl German Hodgkin s Lymphoma Study Group Low acute hematological toxicity during
More informationEvidence-Based Focused Review
Evidence-Based Focused Review Evidence-based focused review of the role of radiation therapy in the treatment of early-stage Hodgkin lymphoma Michael Crump, 1 Jordan Herst, 2 Fulvia Baldassarre, 3 Jonathan
More informationLymphoma update: turning biology into cures. Peter Johnson
Lymphoma update: turning biology into cures Peter Johnson Selected highlights of recent research 1. Using FDG-PET to modify treatment and avoid long term toxicity in Hodgkin lymphoma 2. Understanding how
More informationRadiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationRESEARCH ARTICLE. Ozgur Tanriverdi 1 *, Ibrahim Barista 2, Semra Paydas 3, Erdinc Nayir 4, Yusuf Karakas 2. Abstract. Introduction
DOI:10.22034/APJCP.2017.18.11.3149 RESEARCH ARTICLE Oncologists Perspectives on Consolidation Radiation Treatment after Chemotherapy for Lymphomas: A Survey Study by the Lymphoma Working Committee of the
More informationGuidelines for the first line management of classical Hodgkin lymphoma
guideline Guidelines for the first line management of classical Hodgkin lymphoma George A. Follows, 1 Kirit M. Ardeshna, 2 Sally F. Barrington, 3 Dominic J. Culligan, 4 Peter J. Hoskin, 5 David Linch,
More informationAt initial diagnosis, patients with
Malignant Lymphomas Decision Making and Problem Solving Current treatment and immunotherapy of Hodgkin s lymphoma Beate Klimm Roland Schnell Volker Diehl Andreas Engert The treatment of Hodgkin s lymphoma
More informationHodgkin's Lymphoma. Symptoms. Types
Hodgkin's lymphoma (Hodgkin's disease) usually develops in the lymphatic system, a part of the body's immune system. This system carries disease-fighting white blood cells throughout the body. Lymph tissue
More informationPositron Emission Tomography in the Management of Hodgkin Lymphoma
HODGKIN LYMPHOMA Positron Emission Tomography in the Management of Hodgkin Lymphoma Joseph M. Connors 1 1 BC Cancer Agency, Vancouver, BC Accurate imaging of lymphoma is essential for optimal management.
More informationHodgkin Lymphoma in Older Patients
Hodgkin Lymphoma in Older Patients Andrew M. Evens, DO, MSc March 26 th, 2015 Professor of Medicine Chief, Division of Hematology/Oncology Director, Tufts Cancer Center Tufts Medical Center Elderly Hodgkin
More informationClinical Characteristics and Treatment Response of Hodgkin s Lymphoma in Taiwan
ORIGINAL ARTICLE Clinical Characteristics and Treatment Response of Hodgkin s Lymphoma in Taiwan Shang-Ju Wu, 1 Chien-Yuan Chen, 1 Ih-Jen Su, 2 Jih-Luh Tang, 1 Wen-Chen Chou, 1,3 Bo-Sheng Ko, 1 Sheng-Yi
More informationRadiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2
Radiation and Hodgkin s Disease: A Changing Field Sravana Chennupati Radiation Oncology PGY-2 History of Present Illness 19 yo previously healthy male college student began having pain in his R shoulder
More informationSee accompanying editorial on page J Clin Oncol 34: by American Society of Clinical Oncology INTRODUCTION
VOLUME 34 NUMBER 17 JUNE 10, 2016 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationSeminar. Hodgkin s lymphoma in adults
Hodgkin s lymphoma in adults William Townsend, David Linch Lancet 2012; 380: 836 47 Published Online July 25, 2012 http://dx.doi.org/10.1016/ S0140-6736(12)60035-X Department of Haematology, University
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationHodgkin Lymphoma: Advancing Beyond Standard Management
J a n u a r y 2 0 0 9 w w w. c l i n i c a l a d v a n c e s. c o m V o l u m e 7, I s s u e 1, S u p p l e m e n t 3 G u e s t E d i t o r Bruce D. Cheson, MD, FACP Head of Hematology Lombardi Comprehensive
More informationNodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management
HODGKIN LYMPHOMA: NEW INSIGHTS AND NEW APPROACHES Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management Dennis A. Eichenauer 1,2 and Andreas Engert 1,2 1 First Department
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationLung hilar Ga-67 uptake in patients with lymphoma following chemotherapy
ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 18, No. 5, 391 397, 2004 Lung hilar Ga-67 uptake in patients with lymphoma following chemotherapy Emel Ceylan GUNAY,* Bilge Volkan SALANCI,* Ibrahim BARISTA**
More informationBleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath
Bleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath Rachel Bubik, PharmD, BCPS PGY-2 Hematology/Oncology Pharmacy Resident January 8 th, 2019 2017 MFMER slide-1 Objectives 1. Explain
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationRole of modern radiation therapy in early stage Hodgkin s lymphoma: A young radiation oncologists perspective
reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 246 250 Available online at www.sciencedirect.com jo u r n al hom epage: http://www.elsevier.com/locate/rpor Review Role of modern radiation
More informationFor more than a century after Thomas Hodgkin first described
The new england journal of medicine review article Current Concepts Early-Stage Hodgkin s Lymphoma James O. Armitage, M.D. For more than a century after Thomas Hodgkin first described the disease that
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationWelcome & Introductions
Living with Hodgkin Lymphoma Welcome & Introductions Dr. Lamar s slides are available for download at www.lls.org/programs, under the program listing. 1 Living with Hodgkin Lymphoma Living with Hodgkin
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationBEACOPP-14/ BEACOPP- Escalated
BEACOPP-14/ BEACOPP- Escalated INDICATION Early Stage Classical Hodgkin Lymphoma with positive interim PET-CT (Deauville 3 or more) Advanced Classical Hodgkin lymphoma This protocol should normally be
More informationIAEA Pediatric Radiation Oncology Training Dr Laskar Version 1 June 2009 RADIATION THERAPY FOR PEDIATRIC HODGKIN S DISEASE
RADIATION THERAPY FOR PEDIATRIC HODGKIN S DISEASE THOMAS HODGKIN 1832 On Some Morbid Appearances of the Absorbent Glands & Spleen GLOBAL INCIDENCE Region Cases per 100,000 children United States 0.5 European
More informationFDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-hodgkin lymphoma
Original article Annals of Oncology 16: 1514 1523, 2005 doi:10.1093/annonc/mdi272 Published online 24 June 2005 FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationPositron emission tomography (PET) in residual post-treatment Hodgkin s disease masses
J. Appl. Biomed. 3: 147 153, 2005 ISSN 1214-0287 BRIEF COMMUNICATION Positron emission tomography (PET) in residual post-treatment Hodgkin s disease masses Gustavo H. Marin, Jorge Dellagiovanna, Pablo
More informationReview Article Prognostication and Risk-Adapted Therapy of Hodgkin s Lymphoma Using Positron Emission Tomography
Advances in Hematology Volume 2011, Article ID 271595, 12 pages doi:10.1155/2011/271595 Review Article Prognostication and Risk-Adapted Therapy of Hodgkin s Lymphoma Using Positron Emission Tomography
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Madrid, 25 November 2016 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationHodgkin Lymphoma: Umberto Ricardi
Hodgkin Lymphoma: Radiation Volumes Umberto Ricardi Università di Torino The changing role of RT in the cure of HL From Maximal use as a single agent To Combination of chemotherapy and full dose-full volume
More informationchildren and young people:
Hodgkin lymphoma in children and young people: State of the art Professor W. Hamish Wallace RHSC 2016 Childhood Cancer 1971-2010 One-, Five- and Ten-Year Actuarial Survival (%), Children (Aged 0-14),
More informationOverview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC
2 A C A N A D I A N P E R S P E C T I V E Volume 2 November 2005 Overview The International Conference on Malignant Lymphoma (ICML) is held every three years in Lugano, Switzerland. ICML started nearly
More information